Company profile for Destiny Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Destiny Pharma plc is a clinical stage, biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life‑threatening infections caused by antibiotic resistant bacteria, often referred to as superbugs. Infections caused by antibiot...
Destiny Pharma plc is a clinical stage, biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life‑threatening infections caused by antibiotic resistant bacteria, often referred to as superbugs. Infections caused by antibiotic resistant strains of bacteria continue to rise at an alarming rate and they pose a major threat to public health in the view of the World Health Organization.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Sussex Innovation Centre, Science Park Square, Brighton, BN1 9SB
Telephone
Telephone
+44(0) 1273 704440
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-09-23/emv-capital-acquires-antibiotic-assets-from-destiny-pharma

PHARMAWEB
23 Sep 2025

https://www.fiercebiotech.com/biotech/destiny-goes-private-stay-afloat-after-no-partner-found-anti-infection-drug

FIERCE BIOTECH
15 Jul 2024
Destiny ends COVID collab, Santhera returns lonodelestat
Destiny ends COVID collab, Santhera returns lonodelestat

25 Apr 2024

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/destiny-calls-time-sporegen-covid-collab-while-santhera-hands-lonodelestat-back-spexis

James Waldron FIERCE BIOTECH
25 Apr 2024

https://www.pharmiweb.com/press-release/2023-05-02/destiny-pharma-and-sporegen-announce-update-from-research-collaboration-under-innovate-uk-grant-award-to-develop-a-biotherapeutic-treatment-spor-cov-for-covid-19-and-influenza

PHARMIWEB
02 May 2023

https://endpts.com/uk-biotech-hands-off-mid-stage-c-difficile-drug-in-up-to-570m-deal/

Paul Schloesser ENDPTS
27 Feb 2023
Destiny seals C. diff therapy's phase 3 fate with Sebela
Destiny seals C. diff therapy's phase 3 fate with Sebela

24 Feb 2023

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/destiny-seals-c-diff-therapys-phase-3-fate-sebela

Annalee Armstrong FIERCE BIOTECH
24 Feb 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty